Wells Fargo analyst Mohit Bansal maintained a Hold rating on Pfizer today and set a price target of $28.00. According to TipRanks, Bansal is a 5-star analyst with an average return of 9.2% and a 55.65 ...

In 2026, Pfizer expects adjusted earnings per share in the range of $2.80-$3.00, which represents a decline from the 2025 EPS ...

A big dividend can’t hide the growth problem at Pfizer (PFE), one of the world’s largest pharmaceutical companies. Pfizer has ...

After GSK’s Lymerix, the only Lyme disease vaccine ever approved, was pulled from the market in 2002 amid a safety ...

Pfizer started 2026 on a high note despite ongoing skepticism from retail investors. Click here to find out why PFE stock is ...

High‑yield healthcare stocks are pulling back. See five dividends paying 6% to 14.1% and what their fundamentals reveal for ...

Add Yahoo as a preferred source to see more of our stories on Google. Pfizer is running a Phase III trial of the drug in first-line breast cancer. Credit: ShU studio / Shutterstock.com (ShU studio / ...

Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 ...

A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...

The combination of Roche’s investigational drug, giredestrant, with Pfizer’s Ibrance didn’t lead to a statistically significant improvement among patients with advanced breast cancer.

Investor sentiment toward Pfizer remains cautious despite a significant development in its dermatology pipeline. The pharmaceutical giant announced accelerated plans for a promising new skin treatment ...